Bristol-Myers Squibb Company (BMY) Given Hold Rating at Credit Suisse Group
Bristol-Myers Squibb Company (NYSE:BMY)‘s stock had its “hold” rating reiterated by investment analysts at Credit Suisse Group in a report released on Friday.
Other research analysts have also issued reports about the stock. Jefferies Group LLC reiterated a “buy” rating and set a $64.00 price target on shares of Bristol-Myers Squibb in a research note on Monday, June 5th. BidaskClub upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Vetr lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $61.66 price target on the stock. in a research note on Tuesday, July 25th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Finally, Cowen and Company set a $65.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, July 10th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $62.54.
Bristol-Myers Squibb (NYSE:BMY) traded down 0.76% during midday trading on Friday, hitting $62.36. 2,193,213 shares of the stock traded hands. Bristol-Myers Squibb has a one year low of $46.01 and a one year high of $63.47. The company’s 50 day moving average is $57.32 and its 200-day moving average is $55.65. The company has a market cap of $102.27 billion, a P/E ratio of 22.78 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The business had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same period in the previous year, the business posted $0.69 earnings per share. The business’s revenue was up 5.6% compared to the same quarter last year. On average, equities research analysts forecast that Bristol-Myers Squibb will post $2.98 EPS for the current fiscal year.
WARNING: “Bristol-Myers Squibb Company (BMY) Given Hold Rating at Credit Suisse Group” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/09/08/bristol-myers-squibb-company-bmy-given-hold-rating-at-credit-suisse-group.html.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II purchased 6,000 shares of Bristol-Myers Squibb stock in a transaction on Wednesday, August 2nd. The shares were bought at an average price of $55.94 per share, with a total value of $335,640.00. Following the completion of the acquisition, the director now directly owns 18,000 shares of the company’s stock, valued at $1,006,920. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.23% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in BMY. Beacon Capital Management lifted its stake in shares of Bristol-Myers Squibb by 400.0% during the fourth quarter. Beacon Capital Management now owns 5 shares of the biopharmaceutical company’s stock valued at $0 after buying an additional 4 shares during the period. American National Bank lifted its stake in shares of Bristol-Myers Squibb by 36.0% during the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 508 shares during the period. Tradewinds Capital Management LLC lifted its stake in shares of Bristol-Myers Squibb by 34.6% during the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 500 shares during the period. Penserra Capital Management LLC lifted its stake in shares of Bristol-Myers Squibb by 95.3% during the third quarter. Penserra Capital Management LLC now owns 1,959 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 956 shares during the period. Finally, Atlantic Trust LLC purchased a new position in shares of Bristol-Myers Squibb during the second quarter valued at approximately $111,000. 68.80% of the stock is currently owned by institutional investors.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.